Lumasiran, sold under the brand name Oxlumo, is a medication for the treatment of primary hyperoxaluria type 1 (PH1).

[12] This results in reduction of urinary and plasma oxalate levels, the underlying cause of disease manifestations in people with PH1.

[9][10] The extra oxalate can also build up, and damage other parts of the body, including eyes, heart, skin, and bone.

[10] The FDA granted the application for lumasiran orphan drug and breakthrough therapy designations.

[6] The FDA granted the approval of Oxlumo to Alnylam Pharmaceuticals, Inc.[6] Lumasiran is available under the UK Early Access to Medicines Scheme (EAMS) as of July 2020.

[17][18] The applicant for this medicinal product is Alnylam Netherlands B.V.[17] Lumasiran was approved for medical use in the European Union and in the United States in November 2020.